Samantha C. Shapiro, MD, is a clinician educator who practices telerheumatology and writes for both medical and lay audiences. She earned her medical degree from Baylor College of Medicine, Houston, and was inducted into Alpha Omega Alpha Honor Medical Society. In 2018, she completed her internal medicine residency and rheumatology fellowship training at Johns Hopkins University, Baltimore. Fresh out of training, she founded the Division of Rheumatology at Dell Medical School at The University of Texas at Austin, where she remains an affiliate faculty member. In September 2021, she left her full-time academic position to pursue her main passions: clinical education, patient education, advocacy and international travel. She works with various telehealth services to improve access to rheumatologic care. She educates patients and physicians as a medical writer and enjoys writing for both lay and medical audiences. She is an active member of the ACR, volunteering her time to the ACR’s Insurance Subcommittee.
WASHINGTON, D.C.—Behçet’s disease (BD) is not a common condition, but we frequently receive referrals to evaluate for it in rheumatology clinics because a patient has oral or genital ulcers. So what’s Behçet’s and what’s not? How can we tell the difference? At the ACR Convergence 2024 Review Course, Johannes Nowatzky, MD, director, New York University…
How can we best care for our patients from a joint & cardiovascular perspective? That’s the question Christina Charles-Schoeman, MD, MS, professor of medicine and chief, Division of Rheumatology, University of California Los Angeles Medical Center, Santa Monica, Calif., addressed in a session at ACR Convergence 2024.
In this Review Course at ACR Convergence 2024, Iain McInnes, PhD, FRCP, discussed some of the challenges of RA: Remission is drug maintained, multimorbidity abounds, treatment strategies can be complex, & prevention is not yet possible.
At this ACR Convergence 2024 session, discussion centered on novel techniques that offer hope for developing personalized therapies for pediatric SLE.
Vitamin D has gotten a lot of press over the years. But is it actually worth the hype, especially when it comes to autoimmunity? Does it prevent the onset of autoimmune disease? Does it have a role in treatment? Experts in this ACR Convergence 2024 session helped decipher the role of vitamin D in bone health, immune regulation and infection reduction.
At this ACR Convergence 2024 session, the focus was on the identification & treatment of a newly identified syndrome of undifferentiated recurrent fever (SURF).
Experts address how sex differences affect the clinical presentation, diagnosis, response to therapy and experience of illness for patients with PsA.
At this ACR Convergence 2024 session, two experts spoke about identifying difficult-to-manage patients with spondyloarthritis, differentiating active disease from fibromyalgia & therapy selection in these patients.
The 2024 Dubois Memorial Lecture focused on health inequities with lupus & strategies to close the gap.
WASHINGTON, D.C.—As of November 2024, there are 16 biologic disease-modifying anti-rheumatic drugs (bDMARDs) that are FDA approved for the treatment of psoriatic arthritis (PsA). Incredible news, right? But as my fellowship program director used to say, “There’s no free lunch.” This buffet of options is excellent for our patients, but poses challenges to the practicing…